Zenas BioPharma’s (ZBIO) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Zenas BioPharma (NASDAQ:ZBIO) in a report issued on Friday morning,Benzinga reports. HC Wainwright currently has a $44.00 target price on the stock.

ZBIO has been the subject of several other research reports. Guggenheim increased their price target on Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a report on Monday, March 16th. Zacks Research cut Zenas BioPharma from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 17th. Citigroup reaffirmed a “buy” rating on shares of Zenas BioPharma in a report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Friday, March 27th. Finally, Morgan Stanley raised their target price on Zenas BioPharma from $21.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Thursday. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Zenas BioPharma has an average rating of “Hold” and a consensus target price of $44.29.

Zenas BioPharma Price Performance

NASDAQ:ZBIO opened at $18.34 on Friday. Zenas BioPharma has a one year low of $8.91 and a one year high of $44.60. The company has a debt-to-equity ratio of 1.04, a quick ratio of 5.61 and a current ratio of 11.94. The stock has a market cap of $1.16 billion, a PE ratio of -2.17 and a beta of -0.61. The stock has a 50 day moving average price of $21.21 and a 200 day moving average price of $26.75.

Zenas BioPharma (NASDAQ:ZBIO) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.01. During the same period last year, the firm posted ($0.80) earnings per share. Equities research analysts expect that Zenas BioPharma will post -4.97 EPS for the current fiscal year.

Insider Transactions at Zenas BioPharma

In other news, Director Fairmount Funds Management Llc purchased 150,000 shares of the stock in a transaction dated Tuesday, March 31st. The stock was acquired at an average cost of $20.00 per share, for a total transaction of $3,000,000.00. Following the completion of the transaction, the director directly owned 2,359,025 shares in the company, valued at approximately $47,180,500. This represents a 6.79% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Hongbo Lu purchased 3,768 shares of the stock in a transaction dated Tuesday, March 31st. The shares were purchased at an average price of $18.63 per share, with a total value of $70,197.84. Following the completion of the transaction, the director owned 426,736 shares of the company’s stock, valued at approximately $7,950,091.68. This trade represents a 0.89% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 213,768 shares of company stock worth $4,137,398 over the last ninety days. Company insiders own 22.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ZBIO. Geode Capital Management LLC boosted its position in shares of Zenas BioPharma by 4.6% during the second quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock worth $3,621,000 after buying an additional 16,461 shares during the period. Rhumbline Advisers boosted its position in shares of Zenas BioPharma by 71.3% during the second quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock worth $191,000 after buying an additional 8,207 shares during the period. Sei Investments Co. purchased a new position in Zenas BioPharma in the second quarter valued at $118,000. Bank of America Corp DE boosted its holdings in Zenas BioPharma by 32.3% in the second quarter. Bank of America Corp DE now owns 13,991 shares of the company’s stock valued at $136,000 after purchasing an additional 3,412 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in Zenas BioPharma by 17.2% in the third quarter. Vanguard Group Inc. now owns 1,162,758 shares of the company’s stock valued at $25,813,000 after purchasing an additional 170,546 shares during the period.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.